{"id":5049,"date":"2024-02-13T15:09:38","date_gmt":"2024-02-13T15:09:38","guid":{"rendered":"https:\/\/stuarttherapeutics.com\/?p=5049"},"modified":"2024-02-13T15:11:24","modified_gmt":"2024-02-13T15:11:24","slug":"stuart-therapeutics-announces-chief-medical-and-chief-financial-officer-appointments","status":"publish","type":"post","link":"https:\/\/stuarttherapeutics.com\/stuart-therapeutics-announces-chief-medical-and-chief-financial-officer-appointments\/","title":{"rendered":"Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments"},"content":{"rendered":"
STUART, Fla.<\/span><\/span>,\u00a0Feb. 1, 2024<\/span><\/span>\u00a0\/PRNewswire\/ — Stuart Therapeutics, Inc. (“Stuart<\/span>“), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed\u00a0Jodi Luchs<\/span>, MD to the position of Chief Medical Officer, and\u00a0Don Stires<\/span>\u00a0to the position of Chief Financial Officer.<\/p>\n With the appointment of Dr. Luchs,\u00a0Robert Baratta<\/span>, MD has stepped aside from his current role as Chief Medical Officer but will continue as\u00a0Stuart’s<\/span>\u00a0Executive Chairman of the Board.<\/p>\n